EU Drug Pricing: The Only Way Is Down
Executive Summary
Pricing pressure in Europe is hardly new, but it became a much bigger concern in 2010. The last 18 months have seen some of the most severe and certainly the most numerous, price cuts across the region. Although individual European countries represent only a small share of Big Pharma revenues, the EU as a whole is the world's second-largest market in sales terms, only slightly smaller than the U.S.
You may also be interested in...
European Austerity Drama May Likely Spur The Pace But Not Change The Strategic Plot Line For Pharma
Price cuts and austerity measures made 2011 a bleak year for European pharma. These dynamics are more severe but not new, and likely will accelerate firms’ existing geographic expansion and market access strategies.
Mediator Scandal Provokes Flurry of French Health Reforms But Impact Is Hard To Gauge Until The Dust Settles
France is facing various reforms to its health care system as a direct result of the scandal involving Servier’s diabetes drug Mediator (benfluorex), which may have caused up to 500 deaths.
Mediator Scandal Provokes Flurry of French Health Reforms But Impact Is Hard To Gauge Until The Dust Settles
France is facing various reforms to its health care system as a direct result of the scandal involving Servier’s diabetes drug Mediator (benfluorex), which may have caused up to 500 deaths.